Michael Antonov: From Virtual World Builder to Real-World Drug Designer
Read Full Article on Behind the Breakthroughs
On Behind the Breakthroughs, Deep Origin co-founder Michael Antonov makes the case that real progress in drug discovery comes from pairing machine learning with physics-based simulation and experimental validation — not algorithms alone.
AI is transforming biomedical research, but meaningful advances in drug discovery require more than just increasingly powerful algorithms — they depend on combining machine learning with physics-based simulations, mechanistic models, and rigorous experimental validation. In this episode of Behind the Breakthroughs (Episode 45), Michael Antonov, co-founder of Oculus and computational drug discovery company Deep Origin, shares a pragmatic perspective on AI’s opportunities and limitations in medicine, explaining where it is accelerating innovation and why human expertise and experimental science remain indispensable.
Listen
Also listen on Spotify, Apple Podcasts, and Amazon Music.
Produced and hosted by Jonathan D. Grinstein, PhD. Audio mixed and mastered by Erick Ziegler. Brought to you by Inside Precision Medicine (SAGE Publishing).
